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Editor’s key points
† There is limited
knowledge about the
analgesic requirements
of neonates with Down’s
syndrome.
† This is a challenging
patient group to study.
† This retrospective study
looks at perioperative
management and pain
control using a validated
scale.
† Neonates with Down’s
syndrome did not appear
to have different
analgesic requirements.
† Despite sample size
limitations, this study
provides useful evidence
for future work.
Background. Reports conflict on optimal postoperative analgesic treatment in children with
intellectual disability. We retrospectively compared postoperative analgesics consumption
between neonates with and without Down’s syndrome in relation to anaesthesia
requirements and pain scores.
Methods. We analysed hypnotic and analgesic drug administration, pain scores [COMFORT-
Behaviour (COMFORT-B) scale], and duration of mechanical ventilation during the first 48 h
after surgical repair of congenital duodenal obstruction in neonates, between 1999 and
2011. Data of 15 children with Down’s syndrome were compared with data of 30 children
without Down’s syndrome.
Results. General anaesthesia requirements did not differ. The median (inter-quartile range)
maintenance dose of morphine during the first 24 h after operation was 9.5 (7.8–10.1) mg
kg21 h21 in the Down’s syndrome group vs 7.7 (5.0–10.0) mg kg21 h21 in the control group
(P¼0.46). Morphine doses at postoperative day 2 and COMFORT-B scores at day 1 did not
significantly differ between the two groups. COMFORT-B scores at day two were lower in
children with Down’s syndrome (P¼0.04). The duration of postoperative mechanical
ventilation did not statistically differ between the two groups (P¼0.89).
Conclusions. In this study, neonates with and without Down’s syndrome received adequate
postoperative analgesia, as judged from comparable analgesic consumption and pain
scores. We recommend prospective studies in children of different age groups with
Down’s syndrome and in other groups of intellectually disabled children to provide
further investigation of the hypothesis that intellectual disability predisposes to different
analgesic requirements.
Keywords: anaesthesia, general; analgesia; Down syndrome; infant, newborn; intestinal
atresia
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Research on systematic pain assessment and adequate anal-
gesic therapy in children and neonates is on the rise.1 It is
not clear whether the ‘standard’ dosing regimens are applic-
able to intellectually disabled children,2 although the evidence
indicates potential differences in analgesic requirements for in-
tellectually disabled children. Fewer children with intellectually
disability were assessed for pain after spinal fusion surgery and
they received smaller doses of opioids.3 On the other hand,
Gakhal and colleagues4 found that children with Down’s syn-
drome were more likely to receive morphine on day 3 after
cardiac surgery than were controls.
Most studies in children with intellectual disability are
limited by the sample heterogeneity in terms of aetiologies
and intellectual disability levels. The reported incidence of
congenital duodenal obstruction in children with Down’s syn-
drome is 369 per 10 000 live births, far exceeding that in chil-
dren without Down’s syndrome, from 1.16 to 3.06 per 10 000
live births.5 This makes repair of duodenal obstruction emi-
nently suitable for comparison of anaesthesia, analgesia,
and pain scores between a well-defined group of neonates
likely to have future intellectual disability and a group of neo-
nates with a lesser risk of future intellectual disability.
British Journal of Anaesthesia 108 (2): 295–301 (2012)
Advance Access publication 26 December 2011 . doi:10.1093/bja/aer421
& The Author [2011]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
 at Institute of Social Studies on A
ugust 10, 2015
http://bja.oxfordjournals.org/
D
ow
nloaded from
 
Methods
Participants and setting
After approval of the local ethics review board, we identified
all patients who underwent surgical repair of congenital duo-
denal obstruction between March 1999 and February 2011 in
Erasmus University Medical Centre—Sophia Children’s
Hospital, Rotterdam, the Netherlands, and reviewed their
medical records. The Erasmus MC Department of Paediatric
Surgery and ICU serves as the only level III facility for
those patients in a referral area comprising about 4 million
inhabitants and 35 000 newborns yr21.
Eligible subjects were those who underwent surgical repair
of congenital duodenal obstruction within the first 28 post-
natal days. Exclusion criteria were: sedation or analgesic
treatment during the 24 h before surgery, other surgical
interventions at the same time or within 48 h after primary
surgery for duodenal obstruction, or no digital record
available.
Anaesthesia management
Anaesthesia management is not standardized in our centre
and has changed over the years, reflecting new develop-
ments. Management of neonates with Down’s syndrome
generally does not differ from neonates without Down’s syn-
drome, although, anaesthetists may anticipate possible
airway management difficulties in neonates with Down’s
syndrome. Atracurium was the preferred neuromuscular
blocking agent until around 2008, when it was replaced
with cisatracurium. Until 2008, most patients received barbi-
turates (thiopental or pentothal) as the hypnotic agent,
which was then replaced with propofol. After 2008, a single-
shot caudal block was used more frequently as anaesthetists
became familiar with this technique. Evidence of specific an-
aesthesia for surgical repair of congenital duodenal obstruc-
tion is missing.
Postoperative pain protocol
A postoperative pain protocol has been in place since 1999
(Supplementary Fig. S1). The first step was regular pain as-
sessment by an intensive care nurse; at least every 2 h
during the first postoperative days and then every 8 h. The
nurse used both the COMFORT-Behaviour (COMFORT-B)
scale and the Numeric Rating Scale (NRS) for pain assess-
ment.6 – 8 The COMFORT-B scale includes six items, each
rated from 1 to 5. Adding the ratings for all six items provides
a pain rating between 6 and 30. The COMFORT-B scale has
been validated for use in children with and without Down’s
syndrome.8 9 The NRS score for pain is a validated tool that
asks a proxy (the nurse) to rate pain intensity (0, no pain
at all; 10, worst imaginable pain). The NRS expresses the
observer’s expert rating of the patient’s level of pain, taking
the patients’ circumstances (disease-related, treatment
related, and environmental- and patient-specific) into
account.10 The NRS assessments—part of the pain manage-
ment protocol since 1999—serve to differentiate between
pain and distress. The second step of the protocol is anal-
gesic therapy. At the end of surgery, neonates receive a
loading dose of 100 mg kg21 morphine, followed by a main-
tenance dose of 10 mg kg21 h21. The protocol-associated
decision-tree suggests that score combinations of
COMFORT-B ≥17 and NRS ≥4 indicate moderate to severe
pain, warranting opioid analgesia. Otherwise, maintenance
doses of morphine are gradually decreased on the guidance
of COMFORT-B and NRS scores. The pain management proto-
col makes no difference between children with or without
Down’s syndrome. The sedation algorithm has been
described previously.11
In the study period, four children with Down’s syndrome
and four without had been included in a randomized con-
trolled trial about the potential morphine-sparing effects of
rectal acetaminophen to continuous morphine infusions.12
No differences in outcomes between the two treatment
modes were seen; therefore, those neonates were not
excluded from our study.
Measurements
The following patient characteristics were recorded: sex, ges-
tational age at birth, post-natal age at the day of surgery,
weight at the day of surgery, presence of trisomy 21 and
diagnosis of associated congenital abnormalities (in particu-
lar, cardiac anomalies). We recorded amounts of anaes-
thetics, neuromuscular blocking agents, and analgesics (i.v.
or caudal) given intraoperatively. From the surgeons’ report,
we retrieved the cause of duodenal obstruction (duodenal
atresia, duodenal web, or annular pancreas), duration of
the surgery, and whether a central venous catheter had
been placed. Furthermore, we recorded all hypnotics and
analgesics administered during the first 48 h after operation
and the duration of postoperative mechanical ventilation.
Prospectively collected COMFORT-B scores and NRS ratings
were retrieved from the Patient Data Management System
(PDMS). Postoperative day 1 is defined as 0–24 h after
surgery and postoperative day 2 as 24–48 h after surgery.
Statistical analysis
Data were analysed using SPSS version 19.0 (IBM, Chicago, IL,
USA). The x2 test (or Fisher’s exact test in the case of low pre-
dicted cell counts) was used to compare nominal data for the
neonates with and without Down’s syndrome. Continuous
data are presented as median (inter-quartile range) and
the two groups were compared using the Mann–Whitney
U-test. The duration of morphine use is presented as mean
(SD) and the two groups were compared using the t-test. All
reported P-values are two-sided, and P-values of ,0.05 are
considered to indicate statistical significance.
Results
From 1999 to 2011, 107 children underwent surgical repair of
congenital duodenal obstruction in our hospital. Figure 1
gives a flowchart showing that 45 were included in this
study; that is 15 with Down’s syndrome (Down’s syndrome
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group) and 30 without (control group). The excluded neo-
nates are listed in Figure 1.
Background characteristics of both groups are listed in
Table 1. During surgery, a central venous catheter was
placed in seven of the patients with Down’s syndrome vs
12 of the controls (P¼0.67). Children with Down’s syndrome
had more often a congenital heart disease (P¼0.001),
notably an atrioventricular septal defect. The causes of the
congenital duodenal obstruction were comparable between
the two groups.
General anaesthesia
General anaesthesia was induced i.v. in 14 (93%) of the children
with Down’s syndrome,of whom three received a rapid sequence
induction, while 24 (80%) of the controls were induced i.v., of
whom 12 received a rapid sequence induction (P¼1.00).
The hypnotic agents administered during general anaes-
thesia are listed in Table 2. Five of the children with Down’s
syndrome received a bolus of midazolam before transport
to the intensive care unit (ICU) compared with one in the
control group (P¼0.01).
Fentanyl was administered to 14 (93%) of the children
with Down’s syndrome and 26 (87%) of the children
without Down’s syndrome. The median (IQR) dose was 6.7
(5–10) mg kg21 for the Down’s syndrome group vs 6.7 (4–
10) mg kg21 for the control group (P¼0.69). The others
(one with and four without Down’s syndrome) received
sufentanil. Three of the patients with Down’s syndrome vs
six of the controls received single-shot caudal analgesia
during surgery (P¼1.00). Seven of these patients received
1–7 ml ropivacaine 0.2% and the other two patients 4 and
7 ml bupivacaine 0.25%.
Acetaminophen was administered intraoperatively as a
loading dose in six (40%) of the patients with Down’s syn-
drome vs 13 (43%) of the controls (P¼0.38).
Assessed for eligibility
(n=107)
Patients with Down’s syndrome
(n=36)
Exclusion (n=21)
Inclusion (n=15)
–Post-natal age >28 days (n=8)
–Postoperative caudal analgesia (n=2)
–No digital record (n=9)
–Additional surgical interventions (n=2)
Exclusion (n=41)
–Post-natal age >28 days (n=14)
–Postoperative caudal analgesia (n=2)
–No digital record (n=16)
–Additional surgical interventions (n=8)
–Analgesics <24 h before surgery (n=1)
–Duodenal atresia (n=5)
–Duodenal webbing (n=8)
–Annular pancreas (n=2)
Inclusion (n=30)
–Duodenal atresia (n=19)
–Duodenal webbing (n=4)
–Annular pancreas (n=7)
Patients without Down’s syndrome
(n=71)
Fig 1 Flowchart for the 107 children assessed for eligibility.
Table 1 Patient characteristic, by study group. Data are expressed
as median (IQR) or proportion. IQR, inter-quartile range. *P-value
from x2 test. †P-value from Mann–Whitney U-test. ‡P-value from
Fisher’s exact test
Characteristic Down’s
syndrome
(n515)
Controls
(n530)
P-value
Male/female, n 12/3 9/21 0.002*
Gestational age
(weeks)
37 (36–40) 36 (33–38) 0.021†
Presence of
congenital heart
disease, n (%)
8 (53) 2 (7) 0.001‡
Age at surgery
(days)
3 (1–10) 2 (1–4) 0.30†
Weight at surgery
(kg)
2.8 (2.5–3.0) 2.2 (1.7–2.6) 0.005†
Duration of surgery
(min)
187 (149–201) 167 (144–208) 0.78†
Postoperative
ventilation, n (%)
12 (80) 25 (83) 1.00‡
Duration of
postoperative
ventilation (h)
32 (16–46) 27 (18–46) 0.89†
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Postoperative intensive care treatment
Except one neonate in the control group, all patients received
morphine after operation (Table 3). Continuous morphine ad-
ministration was discontinued within the first 24 h in eight
(53%) of the neonates with Down’s syndrome vs 13 (43%)
of the controls (P¼0.53). The mean (SD) total duration of mor-
phine use was 28.2 (15.6) h in the Down’s syndrome group vs
31.9 (16.8) h in the control group (P¼0.48).
Acetaminophen was administered after operation in 12
(80%) of the patients with Down’s syndrome vs 16 (53%) of
the controls (P¼0.08). Two patients with Down’s syndrome
and three controls received midazolam after operation
(P¼1.00; Table 3).
Postoperative pain scores
Over the first two postoperative days, 429 COMFORT-B and
431 NRS scores had been recorded (Table 4). The median
(IQR) COMFORT-B score after arrival at the ICU was 9 (8–
11) in children with Down’s syndrome vs 10 (8–11) in con-
trols (P¼0.36). The median (IQR) COMFORT-B score at day 2
was 10 (9–11) in children with Down’s syndrome vs 11
(10–12) in controls (P¼0.04). Almost all NRS scores were 3
or lower (low or no pain): 97% in the Down’s syndrome
group vs 96% in the control group (P¼0.43). Scores were 0
(no pain) in 110 (66%) observations in the Down’s syndrome
group vs 217 (74%) in the control group (P¼0.06). The com-
bined scores suggested moderate to severe pain (NRS score
of ≥4 combined with a COMFORT-B score of ≥17) only
once in no more than two patients with Down’s syndrome
and three controls.
Discussion
Our analysis did not reveal any substantial differences in an-
aesthesia and analgesia for congenital duodenal obstruction
repair between neonates with and without Down’s syn-
drome, nor in pain scores. Even the duration of mechanical
ventilation was not longer—as often expected—in the neo-
nates with Down’s syndrome. Neonates with Down’s syn-
drome had a higher gestational age; this could explain
their higher weight at surgery. However, it is unlikely that
this influenced anaesthetic or postoperative management
because medication was calculated per kilogram body
weight. Congenital heart disease was more frequent in
Table 2 Intraoperative analgesics, hypnotics, and neuromuscular blocking agents, by group. *Fisher’s exact test. †x2 test. ‡Mann–Whitney test
Characteristic Down’s syndrome (n515) Controls (n530) P-value
Type of induction
I.V., n (%) 11 (73) 12 (40)
Rapid sequence induction, n (%) 3 (20) 12 (40) 0.06*
Inhalation, n (%) 1 (7) 6 (20)
Hypnotics
Barbiturates, n (%) 12 (80) 18 (60) 0.18†
Median (IQR) dose, mg kg21 4.7 (3.6–5.1) 4.6 (4.3–5.6) 0.63‡
Propofol, n (%) 3 (20) 6 (20) 1.00*
Median (IQR) dose, mg kg21 3.9 (3.6–3.9) 3.5 (2.4–7.3) 1.00‡
Sevoflurane, n (%) 5 (33) 5 (15) 0.20†
Isoflurane, n (%) 4 (27) 13 (43) 0.28†
Midazolam, n (%) 5 (33) 1 (3) 0.01*
Median (IQR) dose, mg kg21 118 (55–419) 91 0.67‡
Neuromuscular blocking agents
Succinylcholine, n (%) 3 (20) 13 (43) 0.12†
Median (IQR) dose, mg kg21 1.9 (1.4–1.9) 1.9 (1.6–2.2) 0.90‡
Atracurium, n (%) 10 (67) 11 (37) 0.06†
Median (IQR) dose, mg kg21 1.0 (0.5–1.3) 1.1 (0.8–1.4) 0.39‡
Cisatracurium, n (%) 4 (27) 14 (47) 0.20†
Median (IQR) dose, mg kg21 197 (155–228) 170 (121–279) 0.80‡
Analgesics
Fentanyl, n (%) 14 (93) 26 (87) 0.65*
Median (IQR) dose, mg kg21 6.7 (5.0–10.1) 6.7 (4.0–9.9) 0.69‡
Sufentanil, n (%) 1 (7) 4 (13) 0.65*
Median (IQR) dose, mg kg21 0.4 0.4 (0.3–0.6) 0.80‡
Caudal block, n (%) 3 (20) 6 (20) 1.00*
Acetaminophen, n (%) 6 (40) 13 (43) 0.83†
Median (IQR) dose, mg kg21 22 (8–28) 25 (8–35) 0.58‡
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neonates with Down’s syndrome, which is consistent with
findings from previous studies.5 13 14 Children with Down’s
syndrome received more often a bolus midazolam before
transport to the ICU. COMFORT-B scores at day 2 were
lower in children with Down’s syndrome than in children
without Down’s syndrome, but the difference is clinically
not significant.
The question arises whether our findings tally with those
of previous studies? Table 5 provides an overview of previous
studies3 4 15 16 and the present study. Valid comparison,
however, is hampered by the different age groups and the
heterogeneity of diagnoses and surgical procedures in the
previous studies. Two reported that the intellectually dis-
abled children received less intraoperative analgesia than
the others. One reported more postoperative analgesia and
one less postoperative analgesia in the intellectually disabled
children. In addition, a questionnaire among physicians
revealed that 89% agreed with the statement that intellec-
tually disabled children receive subtherapeutic doses of
analgesics.17 Two of the previous studies also evaluated
pain scores. One observed lower pain scores in the intellec-
tually disabled children but lacked statistical testing.3 In
the other, pain scores had been documented in only
one-third of the children with cerebral palsy and these did
not differ from those of the children without cerebral
palsy.16 In view of the above, the question remains
whether potential differences in pain experience,18 19 pain
expression, or both of intellectually disabled children influ-
ence analgesic requirements (what they need) or pain man-
agement (what they get) in these children. The COMFORT-B
scale has been validated by our group for the use in 0- to
3-yr-old children with Down’s syndrome as well.9 Therefore,
we have reason to believe that at this age, the pain expres-
sion of children with Down’s syndrome is similar to other chil-
dren. It does remain possible that neonates with Down’s
syndrome experience pain differently. Adults with Down’s
syndrome are reported to be more sensitive for heat pain.20
Since several pain-related genes (ADAMTS5, GRIK1, S100B,
RUNX1, KCNE1, and KCNJ6) are located on chromosome
21,21 it will be important to study the effect of trisomy 21
on pain experience and the pharmacokinetics and pharma-
codynamics of analgesics.2
In the present study, the ICU’s postoperative pain protocol
provided for adequate treatment of potential pain and dis-
tress, as demonstrated by generally low COMFORT-B and
NRS scores in all children. Results from a recent study by
our group suggest that independent of the presence of
Down’s syndrome, neonates, in particular those younger
than 10 days, have impaired pharmacokinetic capacity to
metabolize morphine. This study provided new dosing
recommendations based on a population pharmacokinetic
model of i.v. morphine in children up to the age of 3 yr old.
Simulations showed that a different dosing regimen would
result in a more narrow range of morphine and metabolite
concentrations.22 This new dosing recommendation for mor-
phine entails a 50% reduction in children younger than 10
days old. Since most of the children in our study were
younger than 10 days, the administered doses may therefore
have been to the upside. As such, it might be speculated that
Table 3 Postoperative administration of analgesics and sedatives, by group. *Fisher’s exact test. †Mann–Whitney U-test. ‡x2 test
Characteristic Down’s syndrome Controls P-value
Morphine
Number of patients (%) 15 (100) 29 (97) 1.00*
Loading dose (mg kg21) 100 (87–107) 107 (96–136) 0.09†
Maintenance dose day 1 (mg kg21 h21) 9.5 (7.8–10.1) 7.7 (5.0–10.0) 0.46†
Maintenance dose day 2 (mg kg21 h21) 7.0 (5.0–8.6) 5.0 (5.0–6.3) 0.47†
Acetaminophen
Number of patients (%) 12 (80) 16 (53) 0.08‡
Median (IQR) cumulative dose day 1 ( mg kg21) 46 (29–78) 67 (45–88) 0.21†
Median (IQR) cumulative dose day 2 ( mg kg21) 72 (44–82) 59 (28–77) 0.61†
Midazolam
Number of patients (%) 2 (13) 3 (10) 1.00*
Cumulative dose days 1 and 2 (mg kg21) 398 (107–398) 703 (200–703) 0.40†
Table 4 Postoperative COMFORT-B and NRS* scores, by group.
Data are expressed as median (IQR). *Numeric Rating Scale. †Two
patients without Down’s syndrome were not assessed due to a
short stay on the PICU. ‡Mann–Whitney U-test
Characteristic Down’s
syndrome
(n515)
Controls
(n528)†
P-value‡
Median number of scores per patient
Day 1 6 (3–8) 4 (3–8) 0.30
Day 2 4 (3–6) 3 (3–7) 0.59
Median scores per patient
COMFORT-B day 1 10 (9–11) 10 (9–11) 0.52
COMFORT-B day 2 10 (9–11) 11 (10–12) 0.04
Percentage of NRS scores of 0, i.e. no pain, per patient
Day 1 86 (59–100) 75 (52–100) 0.65
Day 2 100 (59–100) 100 (69–100) 0.63
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the neonates in our analysis may have been pain-free with
even less analgesia. A new pharmacodynamics study is
needed to validate these new dosing recommendations, spe-
cifically also in intellectually disabled children.
Study limitations
Judging from the insignificant differences found between the
two groups, the study could have been underpowered. For
two important outcome parameters, we determined the
sample size required to result in a statistically significant dif-
ference (a of 0.05 and b of 0.80). First, the maintenance dose
of morphine on day 1 was higher in children with Down’s syn-
drome; 76 patients in each group would be required to make
this difference statistically significant. Secondly, 260 patients
in each group would be required to make the difference in
COMFORT-B scores at day 1 statistically significant. Given
the incidence of congenital duodenal obstruction of 1.16–
3.06 per 10 000 live births,5 such a study would be challen-
ging, but may be usefully informed by the current work.
Complications and unexpected events were not registered
during most years of our study period. Therefore, we are not
able to present reliable data regarding complications or un-
expected events.
Conclusions
In this study, both neonates with and without Down’s syn-
drome received adequate postoperative analgesia, as
judged from comparable analgesic consumption and pain
scores. The pain scores were low and this finding suggests
that these neonates, independent of the presence of
Down’s syndrome, might have been pain-free with less
analgesia.
Since evidence is still scarce and contradictory, we recom-
mend prospective multicentre studies evaluating post-
operative pain management in different age groups of
children with Down’s syndrome and in other groups of intel-
lectually disabled children. These studies should preferably
use a randomized controlled study design comparing differ-
ent analgesic regimens. In this way, conclusive evidence on
the premise that intellectual disability predisposes to differ-
ent analgesic requirements can be obtained.
Supplementary material
Supplementary material is available at British Journal of
Anaesthesia online.
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